Overview

Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to collect information regarding the safety and tolerability of mifamurtide (liposomal muramyl tripeptide phosphatidyl ethanolamine; L-MTP-PE).
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.
Treatments:
Acetylmuramyl-Alanyl-Isoglutamine
Mifamurtide